P. falciparum Malaria: Developing a Synthetic Subunit Candidate Vaccine

Malaria is one of the most serious infectious diseases of humans, infecting 5–10% of the world’s population, with 300–600 million clinical cases and more than 2 million deaths annually. Moreover, malaria is a major social and economic burden in endemic areas. In recent years, malaria has spread at an alarming rate owing to the increasing resistance of the parasite to drugs, and the resistance of mosquitoes to insecticides. Therefore, new approaches to combat malaria are urgently needed, and a vaccine is predicted to have the greatest impact in addition to being the most cost-effective control measure.

Vaccine Development

One approach is to design a subunit vaccine that incorporates several malaria protein antigens for which there is evidence of protective immunity from epidemiological data or experimental animal challenge models. Development of such subunit vaccines is critically dependent on the availability of an antigen delivery system to drive suitable protein antigen-specific immune responses in humans. Vaccine formulations have to be highly effective, human-compatible and safe. Production of synthetic or recombinant proteins that stably mimic the native structure of the corresponding malaria antigens to induce effective humoral immune responses is a further major challenge.

Our research

We are addressing both problems by developing synthetic peptide structures that induce cross-reactive antibodies against the parent malaria proteins and by coupling them to the surface of immunopotentiating reconstituted influenza virosomes (IRIVs). In addition we are evaluating the use of so fare uncharacterized predicted proteins of Plasmodium falciparum as potential new candidate vaccine antigens.

AbouZahr C et al. The COVID-19 pandemic: Effects on civil registration of births and deaths and on availability and utility of vital events data. Am J Public Health. 2021(in press). DOI: 10.2105/AJPH.2021.306203

Addo S.O et al. Trends in extrapulmonary TB cases at three teaching hospitals in Ghana, 2008-2017. Public Health Action. 2021;11(1):26-32. DOI: 10.5588/pha.20.0061

Adegnika A.A et al. Embed capacity development within all global health research. BMJ Glob Health. 2021;6(2):e004692. DOI: 10.1136/bmjgh-2020-004692

Aebi N.J et al. Can big data be used to monitor the mental health consequences of COVID-19?. Int J Public Health. 2021;66:633451. DOI: 10.3389/ijph.2021.633451

Agorinya I.A et al. Effect of specificity of health expenditure questions in the measurement of out-of-pocket health expenditure: evidence from field experimental study in Ghana. BMJ Open. 2021;11:e042562. DOI: 10.1136/bmjopen-2020-042562

Akweongo P, Chatio S.T, Owusu R, Salari P, Tediosi F, Aikins M. How does it affect service delivery under the National Health Insurance Scheme in Ghana? Health providers and insurance managers perspective on submission and reimbursement of claims. PLoS One. 2021;16(3):e0247397. DOI: 10.1371/journal.pone.0247397

Aliee M et al. Predicting the impact of COVID-19 interruptions on transmission of gambiense human African trypanosomiasis in two health zones of the Democratic Republic of Congo. Trans R Soc Trop Med Hyg. 2021(in press). DOI: 10.1093/trstmh/trab019

AlKhaldi M et al. Rethinking and strengthening the Global Health Diplomacy through triangulated nexus between policy makers, scientists and the community in light of COVID-19 global crisis. Glob Health Res Policy. 2021;6:12. DOI: 10.1186/s41256-021-00195-2

Anufriyeva V, Pavlova M, Stepurko T, Groot W. Patient satisfaction and patient experience are not interchangeable concepts - authors' reply. Int J Qual Health Care. 2021(in press). DOI: 10.1093/intqhc/mzab024

Arn Karoline. Christian Lengeler: Malaria breitet sich wieder aus [Internet]. Zürich: SRF, 2021. [Date Accessed: 21.04.2021]. Available from: